Diagnosis of non‐follicular Lymphoma (ICD‐10 C83) was confirmed in 2,178 patients, DLBCL (ICD‐10 C83.3) in 819 patients. The analysis was age‐ and gender‐adjusted, observational period was 2014 and 2015. Treatments were analyzed for hospitalization and medication based on ATC code, ...
The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage therapy has been tried for these patients according to their clinical status. We studied ICD (irinotecan, cisplatin and dexamethasone) regimen as salvage chemotherapy ...
Furthermore, patients with a previous diagnosis of HIV infection any time prior to their first DLBCL diagnosis or lymphoma more than a year prior to their first DLBCL diagnosis (defined as ICD-9 histology codes: 9590–9769) were excluded. Further details are reported elsewhere [8]. Outcomes ...
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
doi:10.1200/JCO.2023.41.16_suppl.e195313e19531#Background:Central nervous system (CNS) relapse is an infrequent but serious and challenging complication in diffuse large B-cell lymphoma (DLBCL) that carries a dismal prognosis. While several risk factors have been identified to stratify the risk ...
Incidence of any infections and SARS-CoV-2 infections in patients receiving treatment for follicular lymphoma and diffuse large B-cell lymphoma: Real-world evidence from a large US national claims database.doi:10.1200/JCO.2024.42.16_suppl.e19061...
INTRODUCTION: Previous studies indicate that the risk of venous-thromboembolism (VTE) may be higher among patients with aggressive lymphoma. However, these studies were limited by small sample from single institutions and/or heterogeneous patient populations. There is a need to examine the risk of ...
Patients with an ICD-10-CM diagnosis for DLBCL after October 2015 and no prior ICD-9-CM diagnosis for unspecified DLBCL or primary mediastinal large B-cell lymphoma (PMBCL) where classified as incident; those with such codes were classified as prevalent. An adapted algorithm identified lines of...
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituxima... PURPOSE: The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage ...
The VHA is an equal access system providing a unique environment to investigate cancer disparities across the disease continuum.Methods:This is a retrospective chart review of 4033 randomly selected patients with an ICD code for lymphoma treated within the VHA between 01/01/2011 and 12/31/2017. ...